Modification of histone and α tubulin acetylation by HDAC inhibition was first investigated in the Jurkat T cell leukemia cell lines using different treatment times and dosages of the hydroxamic-derived Trichostatin A (TSA), the Suberoylanilide hydroxamic acid (SAHA), and the benzamide-derived MS-275 HDACi. This evidence concerns the gene HDAC9 and T-cell leukemia.